インスリン抵抗性 - 市場の洞察、疫学、市場予測：2034年

今後数年間で、インスリン抵抗性市場は、この疾患に対する認識の高まりと、世界全体の医療支出の増加により変化するとみられます。

企業や研究機関は、インスリン抵抗性の研究開発に影響を与えうる課題を評価し、その機会を探るべく取り組んでいます。開発中の治療法は、病態を治療/改善するための新規アプローチに焦点を当てています。主要企業はインスリン抵抗性の治療法開発に関与しています。新たな治療法の登場は、インスリン抵抗性市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるインスリン抵抗性市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2034年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 重要な洞察

第2章 インスリン抵抗性のエグゼクティブサマリー

第3章 インスリン抵抗性の競合情報分析

第4章 インスリン抵抗性：市場概要

第5章 インスリン抵抗性：疾患の背景と概要

• イントロダクション
• 兆候と症状
• 病態生理学
• 危険因子
• 診断

第6章 患者動向

第7章 インスリン抵抗性の疫学と患者人口

• 疫学の主な調査結果
• 前提と根拠：主要7ヶ国
• 疫学シナリオ：主要7ヶ国
• 米国
• 欧州5ヶ国
• 日本疫学

第8章 治療アルゴリズム、現在の治療、医療行為

第9章 アンメットニーズ

第10章 インスリン抵抗性治療の主要評価項目

第11章 上市済み製品

第12章 新たな治療法

第13章 インスリン抵抗性：主要7ヶ国市場分析

第14章 属性分析

第15章 主要7ヶ国：市場見通し

• 米国：市場規模
• 欧州5ヶ国：市場規模と展望
• ドイツ市場規模
• フランス市場規模
• イタリア市場規模
• スペイン市場規模
• 英国市場規模
• 日本市場規模

第16章 インスリン抵抗性のアクセスと償還の概要

第17章 KOLの見解

第18章 市場促進要因

第19章 市場の障壁

第20章 付録

第21章 DelveInsightのサービス内容

第22章 免責事項

第23章 DelveInsightについて

List of Tables

• Table 1: 7MM Insulin Resistance Epidemiology (2020-2034)
• Table 2: 7MM Insulin Resistance Diagnosed and Treatable Cases (2020-2034)
• Table 3: Insulin Resistance Epidemiology in the United States (2020-2034)
• Table 4: Insulin Resistance Diagnosed and Treatable Cases in the United States (2020-2034)
• Table 5: Insulin Resistance Epidemiology in Germany (2020-2034)
• Table 6: Insulin Resistance Diagnosed and Treatable Cases in Germany (2020-2034)
• Table 7: Insulin Resistance Epidemiology in France (2020-2034)
• Table 8: Insulin Resistance Diagnosed and Treatable Cases in France (2020-2034)
• Table 9: Insulin Resistance Epidemiology in Italy (2020-2034)
• Table 10: Insulin Resistance Diagnosed and Treatable Cases in Italy (2020-2034)
• Table 11: Insulin Resistance Epidemiology in Spain (2020-2034)
• Table 12: Insulin Resistance Diagnosed and Treatable Cases in Spain (2020-2034)
• Table 13: Insulin Resistance Epidemiology in the UK (2020-2034)
• Table 14: Insulin Resistance Diagnosed and Treatable Cases in the UK (2020-2034)
• Table 15: Insulin Resistance Epidemiology in Japan (2020-2034)
• Table 16: Insulin Resistance Diagnosed and Treatable Cases in Japan (2020-2034)
• Table 17: Drug Name, Clinical Trials by Recruitment status
• Table 18: Drug Name, Clinical Trials by Zone
• Table 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Table 20: Region-wise Market Size in USD, Million (2020-2034)
• Table 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Table 22: United States Market Size in USD, Million (2020-2034)
• Table 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Table 24: Germany Market Size in USD, Million (2020-2034)
• Table 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Table 26: France Market Size in USD, Million (2020-2034)
• Table 27: France Market Size by Therapy in USD, Million (2020-2034)
• Table 28: Italy Market Size in USD, Million (2020-2034)
• Table 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Table 30: Spain Market Size in USD, Million (2020-2034)
• Table 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Table 32: United Kingdom Market Size in USD, Million (2020-2034)
• Table 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Table 34: Japan Market Size in USD, Million (2020-2034)
• Table 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of tables is not exhaustive; the final content may vary

List of Figures

• Figure 1: 7MM Insulin Resistance Epidemiology (2020-2034)
• Figure 2: 7MM Insulin Resistance Diagnosed and Treatable Cases (2020-2034)
• Figure 3: Insulin Resistance Epidemiology in the United States (2020-2034)
• Figure 4: Insulin Resistance Diagnosed and Treatable Cases in the United States (2020-2034)
• Figure 5: Insulin Resistance Epidemiology in Germany (2020-2034)
• Figure 6: Insulin Resistance Diagnosed and Treatable Cases in Germany (2020-2034)
• Figure 7: Insulin Resistance Epidemiology in France (2020-2034)
• Figure 8: Insulin Resistance Diagnosed and Treatable Cases in France (2020-2034)
• Figure 9: Insulin Resistance Epidemiology in Italy (2020-2034)
• Figure 10: Insulin Resistance Diagnosed and Treatable Cases in Italy (2020-2034)
• Figure 11: Insulin Resistance Epidemiology in Spain (2020-2034)
• Figure 12: Insulin Resistance Diagnosed and Treatable Cases in Spain (2020-2034)
• Figure 13: Insulin Resistance Epidemiology in the UK (2020-2034)
• Figure 14: Insulin Resistance Diagnosed and Treatable Cases in the UK (2020-2034)
• Figure 15: Insulin Resistance Epidemiology in Japan (2020-2034)
• Figure 16: Insulin Resistance Diagnosed and Treatable Cases in Japan (2020-2034)
• Figure 17: Drug Name, Clinical Trials by Recruitment status
• Figure 18: Drug Name, Clinical Trials by Zone
• Figure 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Figure 20: Region-wise Market Size in USD, Million (2020-2034)
• Figure 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Figure 22: United States Market Size in USD, Million (2020-2034)
• Figure 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Figure 24: Germany Market Size in USD, Million (2020-2034)
• Figure 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Figure 26: France Market Size in USD, Million (2020-2034)
• Figure 27: France Market Size by Therapy in USD, Million (2020-2034)
• Figure 28: Italy Market Size in USD, Million (2020-2034)
• Figure 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Figure 30: Spain Market Size in USD, Million (2020-2034)
• Figure 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Figure 32: United Kingdom Market Size in USD, Million (2020-2034)
• Figure 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Figure 34: Japan Market Size in USD, Million (2020-2034)
• Figure 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of figures is not exhaustive; the final content may vary

DelveInsight's "Insulin Resistance - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Insulin Resistance, historical and forecasted epidemiology as well as the Insulin Resistance market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Insulin Resistance market report provides current treatment practices, emerging drugs, Insulin Resistance market share of the individual therapies, current and forecasted Insulin Resistance market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Insulin Resistance treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Insulin Resistance Disease Understanding and Treatment Algorithm

The DelveInsight Insulin Resistance market report gives a thorough understanding of the Insulin Resistance by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Insulin Resistance.

Treatment

It covers the details of conventional and current medical therapies available in the Insulin Resistance market for the treatment of the condition. It also provides Insulin Resistance treatment algorithms and guidelines in the United States, Europe, and Japan.

Insulin Resistance Epidemiology

The Insulin Resistance epidemiology division provide insights about historical and current Insulin Resistance patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Insulin Resistance epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Insulin Resistance Epidemiology

The epidemiology segment also provides the Insulin Resistance epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Insulin Resistance Drug Chapters

Drug chapter segment of the Insulin Resistance report encloses the detailed analysis of Insulin Resistance marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Insulin Resistance clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Insulin Resistance treatment.

Insulin Resistance Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Insulin Resistance treatment.

Insulin Resistance Market Outlook

The Insulin Resistance market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Insulin Resistance market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Insulin Resistance market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Insulin Resistance market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Insulin Resistance market in 7MM.

The United States Market Outlook

This section provides the total Insulin Resistance market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Insulin Resistance market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Insulin Resistance market size and market size by therapies in Japan is also mentioned.

Insulin Resistance Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Insulin Resistance market or expected to get launched in the market during the study period 2020-2034. The analysis covers Insulin Resistance market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Insulin Resistance Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Insulin Resistance key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Insulin Resistance emerging therapies.

Reimbursement Scenario in Insulin Resistance

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Insulin Resistance domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Insulin Resistance market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Insulin Resistance Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Insulin Resistance, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Insulin Resistance epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Insulin Resistance are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Insulin Resistance market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Insulin Resistance market

Report Highlights:

• In the coming years, Insulin Resistance market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Insulin Resistance R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Insulin Resistance. Launch of emerging therapies will significantly impact the Insulin Resistance market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Insulin Resistance
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Insulin Resistance Report Insights

• Patient Population
• Therapeutic Approaches
• Insulin Resistance Pipeline Analysis
• Insulin Resistance Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Insulin Resistance Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Insulin Resistance Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Insulin Resistance Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Insulin Resistance market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Insulin Resistance total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Insulin Resistance market size during the forecast period (2024-2034)?
• At what CAGR, the Insulin Resistance market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Insulin Resistance market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Insulin Resistance market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Insulin Resistance?
• What is the historical Insulin Resistance patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Insulin Resistance in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Insulin Resistance?
• Out of all 7MM countries, which country would have the highest prevalent population of Insulin Resistance during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Insulin Resistance treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Insulin Resistance in the USA, Europe, and Japan?
• What are the Insulin Resistance marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Insulin Resistance?
• How many therapies are developed by each company for Insulin Resistance treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Insulin Resistance treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Insulin Resistance therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Insulin Resistance and their status?
• What are the key designations that have been granted for the emerging therapies for Insulin Resistance?
• What are the global historical and forecasted market of Insulin Resistance?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Insulin Resistance market
• To understand the future market competition in the Insulin Resistance market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Insulin Resistance in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Insulin Resistance market
• To understand the future market competition in the Insulin Resistance market

Table of Contents

1. Key Insights

2. Executive Summary of Insulin Resistance

3. Competitive Intelligence Analysis for Insulin Resistance

4. Insulin Resistance: Market Overview at a Glance

• 4.1. Insulin Resistance Total Market Share (%) Distribution in 2020
• 4.2. Insulin Resistance Total Market Share (%) Distribution in 2034

5. Insulin Resistance: Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Insulin Resistance Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Insulin Resistance Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Insulin Resistance Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Insulin Resistance Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Insulin Resistance Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Insulin Resistance Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Insulin Resistance Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Insulin Resistance Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Insulin Resistance Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Insulin Resistance Treatment and Management
• 8.2. Insulin Resistance Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Insulin Resistance Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Insulin Resistance: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Insulin Resistance Market Size in 7MM
• 13.3. Insulin Resistance Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Insulin Resistance Total Market Size in the United States
  • 15.1.2. Insulin Resistance Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Insulin Resistance Total Market Size in Germany
  • 15.3.2. Insulin Resistance Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Insulin Resistance Total Market Size in France
  • 15.4.2. Insulin Resistance Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Insulin Resistance Total Market Size in Italy
  • 15.5.2. Insulin Resistance Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Insulin Resistance Total Market Size in Spain
  • 15.6.2. Insulin Resistance Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Insulin Resistance Total Market Size in the United Kingdom
  • 15.7.2. Insulin Resistance Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Insulin Resistance Total Market Size in Japan
  • 15.8.3. Insulin Resistance Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Insulin Resistance

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.